News
Merck & Co notches up another lung cancer use for Keytruda
Bristol-Myers Squibb’s immunotherapy Opdivo has new competition in small cell lung cancer (SCLC) after the FDA approved its arch-rival, Merck & Co’s Keytruda in the indication.
